These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 18047178

  • 1. In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.
    Asyarie S, Rachmawati H.
    PDA J Pharm Sci Technol; 2007; 61(5):400-10. PubMed ID: 18047178
    [Abstract] [Full Text] [Related]

  • 2. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions.
    Patil MP, Gaikwad NJ.
    Acta Pharm; 2009 Mar; 59(1):57-65. PubMed ID: 19304558
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.
    Biswal S, Sahoo J, Murthy PN, Giradkar RP, Avari JG.
    AAPS PharmSciTech; 2008 Mar; 9(2):563-70. PubMed ID: 18459056
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
    Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ, Liu QW.
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
    Zhaojie M, Ming Z, Shengnan W, Xiaojia B, Hatch GM, Jingkai G, Li C.
    Int J Pharm; 2014 Jun 05; 467(1-2):50-9. PubMed ID: 24607213
    [Abstract] [Full Text] [Related]

  • 10. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.
    Kumar BS, Saraswathi R, Kumar KV, Jha SK, Venkates DP, Dhanaraj SA.
    Drug Deliv; 2014 May 05; 21(3):173-84. PubMed ID: 24102185
    [Abstract] [Full Text] [Related]

  • 11. Preparation of osthole-polymer solid dispersions by hot-melt extrusion for dissolution and bioavailability enhancement.
    Yun F, Kang A, Shan J, Zhao X, Bi X, Li J, Di L.
    Int J Pharm; 2014 Apr 25; 465(1-2):436-43. PubMed ID: 24576810
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of prednisone:polyethylene glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behavior, and formulation parameters.
    Leonardi D, Barrera MG, Lamas MC, Salomón CJ.
    AAPS PharmSciTech; 2007 Dec 14; 8(4):E108. PubMed ID: 18181529
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
    Hussain T, Saeed T, Mumtaz AM, Javaid Z, Abbas K, Awais A, Idrees HA.
    Acta Pol Pharm; 2013 Dec 14; 70(4):749-57. PubMed ID: 23923399
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
    Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.
    Drug Des Devel Ther; 2015 Dec 14; 9():4269-77. PubMed ID: 26345723
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.